Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression.

Park-Min KH, Ji JD, Antoniv T, Reid AC, Silver RB, Humphrey MB, Nakamura M, Ivashkiv LB.

J Immunol. 2009 Aug 15;183(4):2444-55. doi: 10.4049/jimmunol.0804165. Epub 2009 Jul 22.

2.

Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.

Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB.

Arthritis Rheum. 2010 Feb;62(2):402-13. doi: 10.1002/art.27200.

3.

Mechanistic insight into osteoclast differentiation in osteoimmunology.

Takayanagi H.

J Mol Med (Berl). 2005 Mar;83(3):170-9. Epub 2005 Jan 26. Review.

PMID:
15776286
6.

Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors.

Ji JD, Park-Min KH, Shen Z, Fajardo RJ, Goldring SR, McHugh KP, Ivashkiv LB.

J Immunol. 2009 Dec 1;183(11):7223-33. doi: 10.4049/jimmunol.0900072. Epub 2009 Nov 4.

8.

RANKing intracellular signaling in osteoclasts.

Feng X.

IUBMB Life. 2005 Jun;57(6):389-95. Review.

9.

RBP-J imposes a requirement for ITAM-mediated costimulation of osteoclastogenesis.

Li S, Miller CH, Giannopoulou E, Hu X, Ivashkiv LB, Zhao B.

J Clin Invest. 2014 Nov;124(11):5057-73. doi: 10.1172/JCI71882. Epub 2014 Oct 20.

10.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
12.

Novel osteoclast signaling mechanisms.

Shinohara M, Takayanagi H.

Curr Osteoporos Rep. 2007 Jun;5(2):67-72. Review.

PMID:
17521508
13.
14.

TREM-1, a negative regulator of human osteoclastogenesis.

Lee B, Kim JH, Jung JH, Kim TH, Ji JD.

Immunol Lett. 2016 Mar;171:50-9. doi: 10.1016/j.imlet.2016.02.002. Epub 2016 Feb 4.

PMID:
26852644
15.

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.

Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH.

J Cell Physiol. 2008 Nov;217(2):409-22. doi: 10.1002/jcp.21511.

PMID:
18543257
17.

Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.

Yang S, Takahashi N, Yamashita T, Sato N, Takahashi M, Mogi M, Uematsu T, Kobayashi Y, Nakamichi Y, Takeda K, Akira S, Takada H, Udagawa N, Furusawa K.

J Immunol. 2005 Aug 1;175(3):1956-64.

18.

TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.

Kanazawa K, Kudo A.

J Bone Miner Res. 2005 May;20(5):840-7. Epub 2004 Dec 20.

19.

Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.

Zawawi MS, Dharmapatni AA, Cantley MD, McHugh KP, Haynes DR, Crotti TN.

Biochem Biophys Res Commun. 2012 Oct 19;427(2):404-9. doi: 10.1016/j.bbrc.2012.09.077. Epub 2012 Sep 20.

PMID:
23000414
20.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913

Supplemental Content

Support Center